In a significant development within the healthcare and pharmaceutical sectors, Bain Capital is reportedly in advanced discussions to acquire PCI Pharma Services, a prominent contract pharmaceutical manufacturer, for a staggering $10 billion. This deal, if finalized, could reshape the landscape of the contract manufacturing industry, as Bain Capital, a global investment powerhouse, looks to strengthen its portfolio within the growing pharmaceutical services market.

Facing escalating trade tensions and looming tariffs under former U.S. President Donald Trump’s policy trajectory, pharmaceutical giant Merck & Co. $MRK has announced a $1 billion investment in a new biomanufacturing facility in Delaware. The plant will play a pivotal role in reinforcing the company’s domestic production capacity, particularly for its flagship oncology treatment, Keytruda.